The inactive form of glycogen synthase kinase-3β is associated with the development of carcinomas in galectin-3 wild-type mice, but not in galectin-3-deficient mice

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 6, 2012, Pages 547-554

  Mendonça, Daniella Fernandes ^a   Chammas, Roger ^b   Liu, Fu Tong ^c   Nonogaki, Suely ^d   Cardoso, Sergio Vitorino ^a   Loyola, Adriano Mota ^a   de Faria, Paulo Rogério ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Galectin 3; Immunohistochemistry; Mice; Oral carcinogenesis; P GSK3 Ser9; Tongue

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; CARCINOGEN; GALECTIN 3; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; TUMOR MARKER;

ANIMAL; ARTICLE; CELL NUCLEUS; CYTOPLASM; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PRECANCER; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; GALECTIN 3; GLYCOGEN SYNTHASE KINASE 3; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; PRECANCEROUS CONDITIONS; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866053542     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Dumic J, Dabelic S and Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616-635.
2. Cvejic D, Savin S, Petrovic I, Selemetjev S, Paunovic I, Tatic S and Havelka M. Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma. Exp Oncol 2005; 27: 210-214.
3. Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K, Tsutsumi S, Suzuki H, Kuwano H and Raz A. Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of betacatenin. Int J Cancer 2011.
4. Liu FT and Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005; 5: 29-41.
5. Nakahara S, Oka N and Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005; 10: 267-275.
6. Shimura T, Takenaka Y, Fukumori T, Tsutsumi S, Okada K, Hogan V, Kikuchi A, Kuwano H and Raz A. Implication of galectin-3 in Wnt signaling. Cancer Res 2005; 65: 3535-3537.
7. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, Hung MC and Bresalier RS. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase- 3beta activity. Cancer Res 2009; 69: 1343- 1349.
8. Ma C, Wang J, Gao Y, Gao TW, Chen G, Bower KA, Odetallah M, Ding M, Ke Z and Luo J. The role of glycogen synthase kinase 3beta in the transformation of epidermal cells. Cancer Res 2007; 67: 7756-7764.
9. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 2010; 9: 144.
10. Li J, Xing M, Zhu M, Wang X, Wang M, Zhou S, Li N, Wu R and Zhou M. Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett 2008; 272: 91-101.
11. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273: 194- 200.
12. Leis H, Segrelles C, Ruiz S, Santos M and Paramio JM. Expression, localization, and activity of glycogen synthase kinase 3beta during mouse skin tumorigenesis. Mol Carcinog 2002; 35: 180-185.
13. Zheng HC, Xu XY, Xia P, Yu M, Takahashi H and Takano Y. Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas. Hum Pathol 2010; 41: 1255-1264.
14. Wang J, Wang X, Gong W, Mi B, Liu S and Jiang B. Increased expression of beta-catenin, phosphorylated glycogen synthase kinase 3beta, cyclin D1, and c-myc in laterally spreading colorectal tumors. J Histochem Cytochem 2009; 57: 363-371.
15. de Faria PR, Chammas R, de Melo TL, Hsu DK, Liu FT, Nonogaki S, Cardoso SV and Loyola AM. Absence of galectin-3 does not affect the development of experimental tongue carcinomas in mice. Exp Mol Pathol 2011; 90: 189-193.
16. Sant'Ana JMA, Chammas R, Liu F, Nonogaki S, Cardoso SV, Loyola AM and de Faria PR. Activation of the Wnt/beta-catenin signaling pathway during oral carcinogenesis process is not influenced by the absence of galectin-3 in mice. Anticancer Research 2011; 31: 2805- 2811.
17. Hsu DK, Yang RY, Pan Z, Yu L, Salomon DR, Fung-Leung WP and Liu FT. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000; 156: 1073-1083.
18. Lumerman H, Freedman P and Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 321-329.
19. Cardesa A, Gale N, Nadal A and Zidar N. Tumors of the Hypopharynx, Larynx and Trachea. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumors. Lyon: IARC; 2005. p. 118-121.
20. Peters J, Loud J, Dimond E and Jenkins J. Cancer genetics fundamentals. Cancer Nurs 2001; 24: 446-461; quiz 462.
21. Tang XH, Knudsen B, Bemis D, Tickoo S and Gudas LJ. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 2004; 10: 301-313.
22. Steidler NE and Reade PC. Initiation and promotion of experimental oral mucosal carcinogenesis in mice. J Oral Pathol 1986; 15: 43-47.
23. Fronza G, Campomenosi P, Iannone R and Abbondandolo A. The 4-nitroquinoline 1-oxide mutational spectrum in single stranded DNA is characterized by guanine to pyrimidine transversions. Nucleic Acids Res 1992; 20: 1283-1287.
24. Kandarkar SV, Sawant SS and Reade PC. Ultrastructural changes to the palatal mucosa of rats following the application of 4-nitroquinoline- 1-oxide (4NQO) and vitamin C. Oral Oncol 1998; 34: 247-252.
25. Abdel-Aziz HO, Murai Y, Takasaki I, Tabuchi Y, Zheng HC, Nomoto K, Takahashi H, Tsuneyama K, Kato I, Hsu DK, Liu FT, Hiraga K and Takano Y. Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study. J Cancer Res Clin Oncol 2008; 134: 777-788.
26. Eude-Le Parco I, Gendronneau G, Dang T, Delacour D, Thijssen VL, Edelmann W, Peuchmaur M and Poirier F. Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology 2009; 19: 68-75.
27. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A and Raz A. Galectin-3, a novel binding partner of beta-catenin. Cancer Res 2004; 64: 6363-6367.
28. Weinberger PM, Adam BL, Gourin CG, Moretz WH, 3rd, Bollag RJ, Wang BY, Liu Z, Lee JR and Terris DJ. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/ Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2007; 133: 503-510.
29. Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, Janson PO, Hedin L and Sundfeldt K. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 2003; 89: 1298- 1304.
30. Takahashi-Yanaga F and Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008; 20: 581- 589.
31. Farago M, Dominguez I, Landesman-Bollag E, Xu X, Rosner A, Cardiff RD and Seldin DC. Kinase- inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res 2005; 65: 5792-5801.
32. Goto H, Kawano K, Kobayashi I, Sakai H and Yanagisawa S. Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue. Oral Oncol 2002; 38: 549-556.